ARCHIVES

Facility Needs Panel Recommends $4.5-3 billion, Seven Year Program To Be Run By NIGMS Or DRR

This article is from The Cancer Letter archive.

Vol. 14 No. 10 | March 4, 1988

Download PDF Visit The Full Archive

Related Articles

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007

Extent Of Risk Reduction From Ovary Removal Varies According To BRCA Mutation

February 29, 2008

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

September 25, 1998

New Mexico, Michigan Win Saturation Implementation Contracts

June 6, 1975

New Creatinine Test Raises Questions About Accuracy Of Carboplatin Dosing

October 8, 2010

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 16, 1998